---
document_datetime: 2023-09-21 21:01:38
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/palonosetron-hospira-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: palonosetron-hospira-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4064851
conversion_datetime: 2025-12-20 16:06:37.483862
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Palonosetron Hospira

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended no   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0005/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release | 12/12/2018 product                  | on                                          | Annex II and PL                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| T/0004    | Transfer of Marketing Authorisation                                                                                        | 12/09/2018   | 04/10/2018   | SmPC, authorised        |
|-----------|----------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|
| IAIN/0003 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 01/02/2018   | 04/10/2018   | Annex II and PL         |
| N/0002    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 13/11/2017   | 04/10/2018   | PL                      |
| N/0001    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                           | 16/02/2017   | 04/10/2018   | Labelling and PL longer |

Medicinal product no longer authorised